tryptophan 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2780 73-22-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • L-Tryptophan
  • tryptophan
  • tryptophane
  • L-Tryptophane
An essential amino acid that is necessary for normal growth in infants and for NITROGEN balance in adults. It is a precursor of INDOLE ALKALOIDS in plants. It is a precursor of SEROTONIN (hence its use as an antidepressant and sleep aid). It can be a precursor to NIACIN, albeit inefficiently, in mammals.
  • Molecular weight: 204.23
  • Formula: C11H12N2O2
  • CLOGP: -1.57
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 3
  • TPSA: 79.11
  • ALOGS: -2.18
  • ROTB: 3

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
None FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Foetal growth restriction 64.17 28.07 15 639 7538 63480830
Infantile apnoea 45.04 28.07 8 646 1025 63487343
Selective eating disorder 39.48 28.07 8 646 2064 63486304
Cerebral haemorrhage 32.04 28.07 12 642 30717 63457651
Device related sepsis 28.86 28.07 7 647 4087 63484281

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Genital hypoaesthesia 39.98 30.55 6 424 225 34956276
Ejaculation failure 38.96 30.55 7 423 802 34955699
Serotonin syndrome 31.22 30.55 11 419 19922 34936579

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Bronchial hyperreactivity 63.76 25.85 13 926 3027 79740422
Breast disorder 56.26 25.85 11 928 2070 79741379
Genital hypoaesthesia 41.05 25.85 6 933 195 79743254
Ejaculation failure 37.47 25.85 6 933 359 79743090
Serotonin syndrome 32.46 25.85 14 925 45013 79698436

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N06AX02 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTIDEPRESSANTS
Other antidepressants
MeSH PA D000928 Antidepressive Agents
MeSH PA D018687 Antidepressive Agents, Second-Generation
MeSH PA D002491 Central Nervous System Agents
MeSH PA D011619 Psychotropic Drugs
CHEBI has role CHEBI:27027 trace elements
CHEBI has role CHEBI:35469 antidepressants
CHEBI has role CHEBI:50733 Dietary Supplement
CHEBI has role CHEBI:75771 Mus musculus metabolites
CHEBI has role CHEBI:75772 S. cerevisiae metabolites
CHEBI has role CHEBI:76924 plant metabolites
CHEBI has role CHEBI:76971 Escherichia coli metabolites
CHEBI has role CHEBI:77746 Homo sapiens metabolite
CHEBI has role CHEBI:83056 Daphnia magna metabolites

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Classical phenylketonuria contraindication 7573000
Depressive disorder contraindication 35489007
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Schizophrenia contraindication 58214004 DOID:5419
Autoimmune disease contraindication 85828009
Eosinophilia myalgia syndrome contraindication 95416007 DOID:998




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.23 acidic
pKa2 13.4 acidic
pKa3 9.51 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Extracellular calcium-sensing receptor GPCR ALLOSTERIC MODULATOR Kd 4.40 IUPHAR
Myeloperoxidase Enzyme IC50 5.65 CHEMBL
Probable G-protein coupled receptor 139 GPCR AGONIST IC50 4.59 IUPHAR

External reference:

IDSource
4029345 VUID
N0000180301 NUI
4018677 VANDF
4029345 VANDF
C0041249 UMLSCUI
CHEBI:57719 CHEBI
TRP PDB_CHEM_ID
CHEMBL54976 ChEMBL_ID
DB00150 DRUGBANK_ID
D014364 MESH_DESCRIPTOR_UI
6305 PUBCHEM_CID
717 IUPHAR_LIGAND_ID
6173 INN_ID
8DUH1N11BX UNII
10898 RXNORM
12547 MMSL
237270 MMSL
48867 MMSL
NOCODE MMSL
d04732 MMSL
001438 NDDF
108952000 SNOMEDCT_US
54821000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ProcalAmine HUMAN PRESCRIPTION DRUG LABEL 22 0264-1915 INJECTION 0.05 g INTRAVENOUS NDA 24 sections
TrophAmine HUMAN PRESCRIPTION DRUG LABEL 20 0264-1933 SOLUTION 0.20 g INTRAVENOUS NDA 23 sections
TrophAmine HUMAN PRESCRIPTION DRUG LABEL 20 0264-1933 SOLUTION 0.20 g INTRAVENOUS NDA 23 sections
TrophAmine HUMAN PRESCRIPTION DRUG LABEL 20 0264-1933 SOLUTION 0.20 g INTRAVENOUS NDA 23 sections
Plenamine HUMAN PRESCRIPTION DRUG LABEL 17 0264-3200 SOLUTION 250 mg INTRAVENOUS ANDA 20 sections
Plenamine HUMAN PRESCRIPTION DRUG LABEL 17 0264-3205 SOLUTION 250 mg INTRAVENOUS ANDA 20 sections
Plenamine HUMAN PRESCRIPTION DRUG LABEL 17 0264-4500 SOLUTION 250 mg INTRAVENOUS ANDA 20 sections
Plenamine HUMAN PRESCRIPTION DRUG LABEL 17 0264-4500 SOLUTION 250 mg INTRAVENOUS ANDA 20 sections
Plenamine HUMAN PRESCRIPTION DRUG LABEL 17 0264-4500 SOLUTION 250 mg INTRAVENOUS ANDA 20 sections
FreAmine III HUMAN PRESCRIPTION DRUG LABEL 16 0264-9010 INJECTION, SOLUTION 0.15 g INTRAVENOUS NDA 24 sections
FreAmine III HUMAN PRESCRIPTION DRUG LABEL 16 0264-9011 INJECTION, SOLUTION 0.15 g INTRAVENOUS NDA 24 sections
TrophAmine HUMAN PRESCRIPTION DRUG LABEL 20 0264-9341 SOLUTION 0.20 g INTRAVENOUS NDA 23 sections
TrophAmine HUMAN PRESCRIPTION DRUG LABEL 20 0264-9361 SOLUTION 0.12 g INTRAVENOUS NDA 23 sections
HepatAmine HUMAN PRESCRIPTION DRUG LABEL 16 0264-9371 INJECTION, SOLUTION 0.07 g INTRAVENOUS NDA 23 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0180 INJECTION 144 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0180 INJECTION 144 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0184 INJECTION, EMULSION 144 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0184 INJECTION, EMULSION 144 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0188 INJECTION 144 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0188 INJECTION 144 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0194 INJECTION 144 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0194 INJECTION 144 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0198 INJECTION 108 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0198 INJECTION 108 mg INTRAVENOUS NDA 21 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0202 INJECTION 144 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0202 INJECTION 144 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0202 INJECTION 144 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0206 INJECTION 144 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0206 INJECTION 144 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0206 INJECTION 144 mg INTRAVENOUS NDA 20 sections